contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


phase-holographic-phase-holographic-imaging-phi-announces-key-organisational-changes

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

PHI is active in medical technology and develops both hardware and software for quantitative analysis of living cell cultures. The HoloMonitor® products are based on non-invasive QPI technology that collects data on cell quality and are sold globally through distributors with a focus on preclinical cancer research, stem cell research and drug development. Going forward, PHI focuses on developing its products for the clinical market and in regenerative medicine. PHI has offices in Lund, Boston, and Winston-Salem.

Phase Holographic Imaging PHI

Lund, Sweden 26th of June 2025, Phase Holographic Imaging PHI AB ("PHI" or the "Company"), ,a leading provider of advanced holographic imaging solutions, is pleased to announce significant organisatio...

Lund, Sweden 26th of June 2025, Phase Holographic Imaging PHI AB ("PHI" or the "Company"), ,a leading provider of advanced holographic imaging solutions, is pleased to announce significant organisational changes to strengthen its global operations.&nbsp;Håkan Rosvall, currently the President of PHI's US operations, has been appointed the Chief Commercial Officer (CCO) for PHI's global operations. In his new role, Rosvall will oversee the Company's commercial strategy and drive global sales initiatives. Rosvall has been a part of PHI since 2010 and joined the PHI team when the Company had launched its first product - HoloMonitor M3 - and was then responsible for building up the distribution network worldwide. Since then, Rosvall has been in different roles, most recently president of PHI's subsidiary in the USA. Rosvall will start his new position in July 2025 and will relocate back to Sweden to assume his new responsibilities.&nbsp;Additionally, PHI is excited to announce the appointment of Casey Clark, PhD as the new President of PHI's subsidiary in the USA. Casey will be stationed at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, where he will lead the Company's US operations and clinical research. These organisational changes will take effect on 1 July 2025.&nbsp;"We are thrilled to have Håkan Rosvall take on the role of Chief Commercial Officer and lead our global commercial efforts," says Patrik Eschricht, CEO of PHI. "His extensive experience and proven track record in the industry make him the ideal candidate to drive our growth and success on a global scale. We also look forward to Casey Clark leading our US operations. We have great faith that his decade of biomedical expertise will push our product forward into new applications."&nbsp;For more information about PHI, please contact:Patrik Eschricht, CEOE-mail: <a href="mailto:ir@phiab.com">ir@phiab.com</a>Website: www.phiab.com&nbsp;About PHIPhase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI's current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology - an innovative approach to cell quality evaluation. QPI offers a detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden; Boston, MA; and Winston-Salem, NC.&nbsp; <div></div>

Phase Holographic: PHASE HOLOGRAPHIC IMAGING PHI Announces Key Organisational Changes